A study on the feasibility of the clinical sequence in acute myeloid leukemia
Not Applicable
- Conditions
- AML (acute myeloid leukemia)
- Registration Number
- JPRN-UMIN000035041
- Lead Sponsor
- Japan Adult Leukemia Study Group(JALSG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up continuing
- Sex
- All
- Target Recruitment
- 602
Inclusion Criteria
Not provided
Exclusion Criteria
(1)Those registered in an interventional study prescribing treatment by anti-cancer drugs (2)Diagnosed with APL with PML-RARA, Myeloid sarcoma (3)With active multiple cancers, poorly controlled diabetes, severe infections
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Characterization of newly diagnosed AML which have low frequency gene mutation
- Secondary Outcome Measures
Name Time Method (1) Percentage of gene mutation identified as PAF (2) Average number of days required to return gene mutation analysis information to the attending doctor (3) Percentage of analysis failure in genetic mutation (4) Percentage of cases that received targeting therapy based on PAF reported from expert panel. (5) Percentage of cases in which PAF reported from expert panel were used to determine the management of AML. (6) Relationship between gene mutation and complete remission rates of initial treatment (7) Relationship between gene mutation and survival rates (8) Percentage of cases which needed genetic counseling PAF is defined as a gene mutation that can provide information on WHO classification (WHO revised 4th edition), AML risk classification by ELN or NCCN, or gene mutations mentioned in genome guideline published by JSH.